ANDA Submissions Drop To Start FY2021
Perhaps Forced Down By COVID-19
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
You may also be interested in...
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.